| Oncogenic signaling of class I PI3K isoforms. | None |
| Comprehensive analysis of oncogenic effects of PIK3CA mutations in human mammary epithelial cells. | None |
| The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. | None |
| study reports a 3.0 angstrom resolution structure of a complex between p110alpha and a polypeptide containing the p110alpha-binding domains of p85alpha; results suggest specific mechanisms for the effect of oncogenic mutations in p110alpha and p85alpha | None |
| structure of the complex between the catalytic subunit of PI3Kalpha, p110alpha, & a portion of its regulatory subunit, p85alpha reveals the majority of the oncogenic mutations occur at the interfaces between p110 domains & between p110 & p85 domains | None |
| Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. | None |
| Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. | None |
| Class I PI3K in oncogenic cellular transformation. | None |
| PIK3CA cooperates with other phosphatidylinositol 3 -kinase pathway mutations to effect oncogenic transformation. | None |
| Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome. | None |
| Oncogenic H-Ras and PI3K signaling can inhibit E-cadherin-dependent apoptosis and promote cell survival after photodynamic therapy in mouse keratinocytes. | None |
| Amplifications of 3q26.32 harboring the oncogene PIK3CA were associated with poor prognosis and segregated with the aggressive transcriptional cluster. | None |
| Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways. | None |
| The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. | None |
| AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. | None |
| Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. | None |
| Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha. | None |
| WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signaling and inhibits the proliferation of transformed cells with oncogenic PI3K mutant. | None |
| Oncogenic mutations of PIK3CA in human cancers. | None |
| The PI3K-Akt mediates oncogenic Met-induced centrosome amplification and chromosome instability. | None |